FAMAR Group Expands Its Manufacturing Reach with New Acquisition in Germany

FAMAR Group Expands into Germany with Strategic Acquisition

FAMAR Group, a prominent European contract development and manufacturing organization (CDMO) in the pharmaceutical sector, has taken a significant step in its growth journey by announcing the acquisition of a sterile production site in Homburg, Germany. This facility was previously owned by MiP Pharma and marks a crucial milestone for FAMAR as it seeks to bolster its manufacturing capabilities in high-value dosage forms.

Strategic Importance of the Acquisition

The agreement to acquire the Homburg facility underscores FAMAR's commitment to expanding its footprint in the pharmaceutical industry, particularly in the fields of aseptic and lyophilized fill-finish processes. The company aims to enhance its offering by leveraging the state-of-the-art technologies and established infrastructure available at the site. With this acquisition, FAMAR will operate a total of seven production facilities across Europe, significantly augmenting its capacity to deliver flexible, high-quality production solutions tailored to the needs of customers.

Konstantinos Rengis, CEO of FAMAR Group, expressed his excitement: "The Homburg site offers world-class sterile infrastructure, newly installed quality control and microbiology laboratories, along with a skilled workforce. This investment aligns perfectly with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with the highest standards of manufacturing services. We are proud to welcome the Homburg team to the FAMAR family and look forward to a fruitful collaboration."

Modernization and Employment Transition

The Homburg facility has recently undergone significant investments and modernization, positioning it as a competitive player in the market for global pharmaceutical specialists. Approximately 100 employees currently working at the site will transition to FAMAR, ensuring continuity and retaining essential knowledge within the organization.

Dr. Friedrich Sernetz, CEO of MiP Pharma, commented on the transaction, stating, "Thanks to previous investments, the Homburg facility has become an attractive site for global specialists in the pharmaceutical sector. With FAMAR, we've found a buyer committed to further developing the site, thereby securing jobs and laying the groundwork for future growth. This allows us to concentrate on our core competency—marketing our medicines—and accelerate our overall growth."

Future Outlook and Industry Impact

The acquisition of the Homburg site enables FAMAR to develop a multi-customer CDMO platform, aligned with its ambition to lead in complex, high-value pharmaceutical manufacturing. The move not only strengthens FAMAR's market position but also emphasizes its commitment to meet the increasing demands of the global healthcare market.

Matthew Strassberg of MidEuropa, noted for his involvement in the transaction, shared his enthusiasm, “We are pleased to support FAMAR as it enhances its capabilities for a diverse and global customer base. This acquisition is a testament to our commitment to helping FAMAR expand into value-added formulations and services.”

About FAMAR Group

FAMAR is recognized as a leading provider of pharmaceutical and cosmetic manufacturing and development services in Europe, with a storied legacy spanning 75 years. The company delivers a diverse range of high-quality dosage forms, including sterile liquids, solids, and semi-solids, to clients across more than 80 international markets. Operating across a network of production facilities and research & development centers in Spain, Italy, and Greece, FAMAR prides itself on its capability to supply over 1,700 different products.

About MiP Pharma Group

MiP Pharma Group, on the other hand, specializes in prescription generics, primarily focusing on antibiotics and over-the-counter medicines, with a robust presence in the hospital business and targeting specific specialist groups. With a workforce of over 200 employees, MiP Pharma has established a solid reputation in the market, reporting sales of around 50 million euros in the past financial year.

With the acquisition of the Homburg facility, FAMAR Group is set to carve a significant niche in the pharmaceutical manufacturing sector, ensuring that it continues to meet the evolving demands of the global market while providing high-quality production solutions.